Vesicular monoamine transporter type 2 (VMAT2) inhibitors are usually considered the drugs of choice for the management of chorea, except for patients with depression, due to the risk of worsening depression and suicidality. The gene discussed is SLC18A2; the disease is depressive symptom measurement.